Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,615
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

A Dabana Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
C Gonninb Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
L Phanc ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie; Hǒpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, FranceView further author information
,
A Saldmannb Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
C Granierb Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France;d INSERM U970, PARCC, Université Paris-Cité, Paris, FranceView further author information
,
A Lillo-Lelouete Department of Pharmacovigilance, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
C Le Bellere Department of Pharmacovigilance, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
J Pouchotf Department of Internal Medicine, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
l Weissg Department of Clinical Immunology, Hôpital Hôtel-Dieu, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
E Tartourb Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France;d INSERM U970, PARCC, Université Paris-Cité, Paris, FranceView further author information
,
E Fabred INSERM U970, PARCC, Université Paris-Cité, Paris, France;h Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, FranceView further author information
,
J Medionia Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceView further author information
,
S Oudarda Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France;d INSERM U970, PARCC, Université Paris-Cité, Paris, FranceView further author information
,
YA Vanoa Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France;i Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, FranceView further author information
,
MA Dragon-Dureyb Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, France;i Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, FranceView further author information
&
A. Simonaggioa Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceCorrespondence[email protected]
View further author information
 show all
Article: 2204754 | Received 24 Jan 2023, Accepted 16 Apr 2023, Published online: 11 May 2023

References

  • Hirsch L, Zitvogel L, Eggermont A, Marabelle A. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br J Cancer Janv. 2019;120:3‑5.
  • Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2 mar 2020;3(3):e200423. doi:10.1001/jamanetworkopen.2020.0423.
  • Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, Péron J, “A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.” Int J Cancer 145, no. 3 (2019 1): 639‑48. doi:10.1002/ijc.32132.
  • Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol Août. 2016;13(8):473‑86. doi:10.1038/nrclinonc.2016.58.
  • Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, et al. Management of toxicities from immunotherapy: eSMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol déc. 2022;33(12):1217‑38. doi:10.1016/j.annonc.2022.10.001.
  • Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. JCO. 2018 févr 14;36(17):1714–9. doi:10.1200/JCO.2017.77.6385. 2017.77.6385.
  • Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer Juin. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435.
  • Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018 déc 1;4(12):1721‑8. doi:10.1001/jamaoncol.2018.3923.
  • Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 26 sept 2017;117(7):913‑20. doi:10.1038/bjc.2017.274.
  • Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J. Vaccinia virus-based vector against infectious diseases and tumors. Human Vacc Immunother. 2021 juin 3;17(6):1578‑85. doi:10.1080/21645515.2020.1840887.
  • Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, et al. Profiling preexisting antibodies in patients treated with anti–PD-1 therapy for advanced non–small cell lung cancer. JAMA Oncol. 1 mar 2019;5(3):376‑83. doi:10.1001/jamaoncol.2018.5860.
  • Izawa N, Shiokawa H, Onuki R, Hamaji K, Morikawa K, Saji H, Ohashi H, Kasugai S, Hayakawa N, Ohara T, Sunakawa Y , et al. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study. ESMO Open. 2022 Apr; 7(2):100415. doi:10.1016/j.esmoop.2022.100415. Epub 2022 Mar 2. PMID: 35247869. PMCID: PMC9058890.
  • Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B. Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie avr. 2016;71(2):179‑86. doi:10.1016/j.therap.2016.02.010.
  • von Mühlen CA, Garcia-De La Torre I, Infantino M, Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Herold M, et al. How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. Immunol Res. 2021 déc;69(6):594‑608. doi:10.1007/s12026-021-09233-0.
  • Giannicola R, D’Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, et al. Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab. Mol Clin Oncol juill. 2019;11(1):81‑90. doi:10.3892/mco.2019.1859.
  • Labadzhyan A, Wentzel K, Hamid O, Chow K, Kim S, Piro L, Melmed S. Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: a prospective study. J Clin Endocrinol Metab. 18 mars 2022;dgac161;107(7):1976–1982. doi:10.1210/clinem/dgac161.
  • Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc. 1 mars 2018;2(3):241‑51. doi:10.1210/js.2017-00432.
  • Ghosh N, Postow M, Zhu C, Jannat-Khah D, Li QZ, Vitone G, Chan KK, Bass AR. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. J Immunother Cancer Janv. 2022;10(1):e004008. doi:10.1136/jitc-2021-004008.
  • Shankar B, Zhang J, Naqash AR, Patrick M F, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer. JAMA Oncol. 2020 déc 1;6(12):1952. doi:10.1001/jamaoncol.2020.5012.
  • Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist. 2018 nov;23(11):1358‑65. doi:10.1634/theoncologist.2017-0384.
  • Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother Janv. 2020;43(1):1‑7. doi:10.1097/CJI.0000000000000300.
  • Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, Otsubo K, Iwama E, Inoue H, Masuda S, et al. Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer Avr. 2019;130:5‑9. doi:10.1016/j.lungcan.2019.01.014.
  • Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M, et al. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Cancer Med. 16 mars 2022;11(16):3074–3083. doi:10.1002/cam4.4675.
  • Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol. 2020 juin 1;22(6):919‑27. doi:10.1007/s12094-019-02214-8.
  • Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Shinomiya S, Akagami T, Imai H, Kobayashi K, et al. Efficacy and feasibility of programmed death-1/programmed death ligand-1 blockade therapy in non-small cell lung cancer patients with high antinuclear antibody titers. Front Oncol. 15 mars 2021;11:610952. 10.3389/fonc.2021.610952.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.